Sp438
MICROBIAL BILE ACID MODULATION AND IT'S ROLE IN METABOLIC HOMESTASIS
Date
May 19, 2024
Presenters
Tracks
Related Products
SAFETY OUTCOMES AND CONCOMITANT MEDICATION CHANGES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE BEING TREATED WITH RBX2660 FOR RECURRENT <i>CLOSTRIDIOIDES DIFFICILE</i> INFECTION
BACKGROUND: Recurrent _Clostridioides difficile _infection (rCDI) is a debilitating disease associated with significant healthcare burden and low quality of life. The greatest risk factor for rCDI is a history of recurrence, although older age (≥65 years) and comorbidities also increase risk…
PREDICTING BOWEL SURGERY IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH C. DIFFICILE INFECTION: A DYNAMIC MACHINE LEARNING APPROACH USING EHR DATA
The risk of bowel surgery in patients with Inflammatory Bowel Disease (IBD) and Clostridioides difficile infection (CDI) can change rapidly over the course of the disease…
DURABILITY OF THE CLINICAL RESPONSE TO SER-109, AN INVESTIGATIONAL ORAL MICROBIOME THERAPEUTIC, IN A PHASE 3 OPEN-LABEL TRIAL (ECOSPOR IV) IN PATIENTS WITH RECURRENT <i>CLOSTRIDIOIDES DIFFICILE</i> INFECTION
BACKGROUND: Recurrent _Clostridioides difficile _infection (rCDI) is a debilitating disease associated with significant healthcare burden and low quality of life. The greatest risk factor for rCDI is a history of recurrence, although older age (≥65 years) and comorbidities also increase risk…
